Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
NCT03821623Phase 2Active, not recruiting
- Start
- May 2019
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertension (HTN) comparing Nicotinamide riboside with Placebo (2 arms). Primary endpoint: Systolic blood pressure at 3 months. Started May 2019; status: active, not recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03821623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821623.